Author

K. R. Hall

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Organism:E. coli· 1 Research Focus:perturbation response prediction· 1 Research Focus:protein folding & dynamics· 1 Assay:protein sequence· 1

Frequent Co-Authors

D. F. Ackerley· 2 shared E. M. Williams· 2 shared A. Calof· 1 shared A. D. Lander· 1 shared A. v. Sharrock· 1 shared D. Ding· 1 shared D. Meir-Levi· 1 shared D. T. White· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

D. F. Ackerley

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A giant leap in sequence space reveals the intracellular complexities of evolving a new function

K. R. Hall, K. J. Robins, M. H. Rich, M. J. Calcott, J. Copp, E. M. Williams, R. F. Little, R. Schwörer, G. B. Evans, W. M. Patrick, D. F. Ackerley

The paper evolves an enzyme to detoxify chloramphenicol, revealing that endogenous substrates significantly influence evolutionary trajectories through epistatic interactions.

bioRxiv · May 27, 2020 · PreprintBiochemistry

NTR 2.0: a rationally-engineered prodrug converting enzyme with substantially enhanced efficacy for targeted cell ablation

A. v. Sharrock, T. S. Mulligan, K. R. Hall, E. M. Williams, D. T. White, L. Zhang, F. Matthews, S. Nimmagadda, S. Washington, K. Le, D. Meir-Levi, O. L. Cox, M. T. Saxena, A. Calof, M. E. Lopez-Burks, , J. S. Mumm

This paper describes the development of NTR 2.0, a modified nitroreductase with significantly improved efficacy for targeted cell ablation using metronidazole.

bioRxiv · May 22, 2020Cell Biology